As of 2024-12-14, the Relative Valuation of Helix Biopharma Corp (HBP.TO) is (0.02) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.87 CAD, the upside of Helix Biopharma Corp based on Relative Valuation is -102.2%.
The range of the Relative Valuation is (0.02) - (0.06) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.1x - 0.3x | 0.1x |
| Forward P/E multiples | 0.1x - 0.3x | 0.1x |
| Fair Price | (0.02) - (0.06) | (0.02) |
| Upside | -101.7% - -106.5% | -102.2% |
| Date | P/E |
| 2024-12-04 | -5.29 |
| 2024-12-03 | -5.29 |
| 2024-12-02 | -5.03 |
| 2024-11-29 | -4.60 |
| 2024-11-28 | -4.39 |
| 2024-11-27 | -4.18 |
| 2024-11-26 | -4.44 |
| 2024-11-25 | -4.34 |
| 2024-11-22 | -4.07 |
| 2024-11-21 | -3.70 |
| 2024-11-20 | -3.70 |
| 2024-11-19 | -3.76 |
| 2024-11-18 | -3.70 |
| 2024-11-15 | -3.60 |
| 2024-11-14 | -3.60 |
| 2024-11-13 | -3.54 |
| 2024-11-12 | -3.70 |
| 2024-11-11 | -3.86 |
| 2024-11-08 | -3.97 |
| 2024-11-07 | -4.23 |
| 2024-11-06 | -3.02 |
| 2024-11-05 | -3.76 |
| 2024-11-04 | -4.02 |
| 2024-11-01 | -4.13 |
| 2024-10-31 | -4.34 |
| 2024-10-29 | -4.76 |
| 2024-10-28 | -5.34 |
| 2024-10-25 | -5.29 |
| 2024-10-24 | -5.98 |
| 2024-10-23 | -5.77 |
| 2024-10-22 | -6.19 |
| 2024-10-21 | -5.66 |
| 2024-10-18 | -5.98 |
| 2024-10-17 | -6.51 |
| 2024-10-16 | -7.09 |
| 2024-10-15 | -6.67 |
| 2024-10-11 | -6.56 |
| 2024-10-10 | -5.29 |
| 2024-10-09 | -5.71 |
| 2024-10-08 | -5.34 |
| 2024-10-07 | -5.98 |
| 2024-10-04 | -6.19 |
| 2024-10-03 | -6.03 |
| 2024-10-02 | -6.30 |
| 2024-10-01 | -5.87 |
| 2024-09-30 | -6.30 |
| 2024-09-27 | -6.19 |
| 2024-09-26 | -6.30 |
| 2024-09-25 | -6.30 |
| 2024-09-24 | -6.30 |